Skip to main content
DCOY
NASDAQ Life Sciences

Decoy Therapeutics Reports Q2 Loss, Going Concern Warning, and Nasdaq Delisting Risk

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.6
Mkt Cap
$2.125M
52W Low
$3.51
52W High
$106.2
52W Position info
2.6% above low
Off High info
97% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

DCOY is trading near its 52-week low of $3.51 (2.6% above the low) on light trading volume (0.1× avg).

Summary

Decoy Therapeutics reported a $4.6 million net loss for H1 2026, warned of going concern doubts, and disclosed a new Nasdaq delisting risk. The stock trades near its 52-week low.


Key Events · Earnings and Guidance · DCOY

  • Going Concern Warning

    The company states there is substantial doubt about its ability to continue as a going concern, with cash of $8.3 million as of June 30, 2026, expected to fund operations only into late 2026.

  • Nasdaq Delisting Risk

    A new risk factor discloses that if the SEC approves Nasdaq's proposed $5 million market value standard, Decoy's common stock could be imminently delisted because its market value is below the threshold.

  • H1 2026 Net Loss

    Net loss for the six months ended June 30, 2026 was $4.6 million, compared to $2.7 million in the prior year period, driven by increased R&D spending on the IMP3ACT platform.

  • Private Placement Details

    The 10-Q confirms the June 29, 2026 private placement raised $3.5 million upfront at $5.91 per share, with milestone warrants potentially adding up to $17.5 million more if exercised.


Analysis · DCOY · Life Sciences

Decoy Therapeutics' 10-Q reveals a $4.6 million net loss for the first half of 2026, cash of $8.3 million, and a going concern warning stating substantial doubt about its ability to continue operations. The company also disclosed a new risk factor regarding Nasdaq's proposed $5 million market value standard, which could lead to imminent delisting if approved. The stock trades near its 52-week low at $3.60, and the company's market cap is only about $2.1 million, making the delisting risk acute.

At the time of this filing, DCOY was trading at $3.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $3.51 to $106.20. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

DCOY - Latest Insights

DCOY
Jul 27, 2026, 9:00 AM EDT
Source: PR Newswire
Importance Score:
8
Price at Filing: $5.04
Real-time Price: $3.60 info
Change: -$1.44 (-29%) info
Market Cap: $2.125M info
DCOY
Jul 24, 2026, 4:05 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $5.04
Real-time Price: $3.60 info
Change: -$1.44 (-29%) info
Market Cap: $2.125M info
DCOY
Jul 10, 2026, 4:26 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $5.91
Real-time Price: $3.60 info
Change: -$2.31 (-39%) info
Market Cap: $2.125M info
DCOY
Jun 29, 2026, 6:03 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $12.34
Real-time Price: $3.60 info
Change: -$8.74 (-71%) info
Market Cap: $2.125M info
DCOY
Jun 26, 2026, 8:11 PM EDT
Source: PR Newswire
Importance Score:
10
Price at Filing: $5.90
Real-time Price: $3.60 info
Change: -$2.30 (-39%) info
Market Cap: $2.125M info